Streetbeat News

Stock Prices

MDGL

HC Wainwright & Co. analyst Ed Arce has reaffirmed a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $225 to $275.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:52 pm

FRTX

Fresh Tracks Therapeutics (FRTX) reported a significant increase in Q3 earnings to $0.32 per share, up from a loss of $(2.07) per share year-over-year. Sales also saw a substantial rise to $7.99M, a 1.54K percent increase from $486.00K in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:51 pm

MGM

Morgan Stanley analyst Stephen Grambling has maintained an Equal-Weight rating on MGM Resorts International (NYSE:MGM) but has lowered the price target from $42 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:50 pm

HYMTF

Hyundai Motor Co has initiated the construction of a new $1.53 billion electric vehicle (EV) plant in Ulsan, South Korea. The facility is expected to produce 200,000 EVs annually, with full-scale construction starting in Q4 2023 and mass production commencing in Q1 2026. The first model to be produced is anticipated to be a Genesis electric SUV. Hyundai recently reported an 8.7% revenue growth in Q3 FY23 and a 33.3% increase in sales of electrified models.

Portfolio Pulse from Lekha Gupta

November 13, 2023 | 1:50 pm

GALT

Galectin Therapeutics (NASDAQ:GALT) reported Q3 earnings with an EPS of $-0.24, missing estimates by 50%. The company's revenue was unchanged from the same period last year. Previously, GALT beat EPS estimates which led to a 7.38% share price increase the following day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 1:50 pm

MBOT

Microbot Medical Inc. (MBOT) has announced the successful completion of the Electromagnetic Compatibility (EMC) testing, a part of the Verification and Validation (V&V) process for its LIBERTY Robotic Surgical System. This step is crucial for the Investigational Device Exemption (IDE) submission to the FDA, which is required to start clinical trials in the US. The company is committed to completing additional V&V testing soon, aiming to begin its first clinical trial.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:50 pm

WYNN

Wynn Resorts, Limited (NASDAQ:WYNN) exceeded third quarter earnings expectations with an operating revenue of $1.67 billion and adjusted EPS of 99 cents, surpassing the consensus estimate of 75 cents. The article also discusses how to earn a monthly income from Wynn Resorts' dividends, which currently yield 1.17%. It explains the number of shares needed to achieve a $500 or $100 monthly dividend income. The dividend yield's variability with stock price and dividend changes is highlighted. WYNN shares dropped 5.7% to close at $85.49 on Friday.

Portfolio Pulse from Lisa Levin

November 13, 2023 | 1:49 pm

VEEE

Twin Vee PowerCats (NASDAQ:VEEE) reported a larger Q3 loss of $(0.20) per share compared to $(0.13) YoY, with sales declining to $8.08M from $8.81M YoY, indicating a 53.85% increase in losses and an 8.35% decrease in sales.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:49 pm

MMAT

Meta Materials (NASDAQ:MMAT) reported Q3 EPS of $(0.02), which was in line with analyst estimates, but sales of $2.20M fell short of the expected $2.50M. This represents a 71.43% improvement in EPS and a 10.42% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:47 pm

HCTI

Healthcare Triangle (HCTI) reported a narrower Q3 loss of $(0.46) per share compared to $(0.70) per share in the same quarter last year. However, sales declined to $7.80M from $11.90M in the same period, representing a 34.45% decrease.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:46 pm